Who
Scott T. Rottinghaus
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Enanta Pharmaceuticals.
In numbers
- Trades disclosed
- 30
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $214K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 8 Aug 2022
- Last trade
- 8 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Aug 2026filed 10 Aug 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $20K1,467 at $13.34 | filing |
| 8 Aug 2026filed 10 Aug 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $20K1,467 at $13.34 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,650 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —5,225 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $49K3,413 at $14.25 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,650 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —5,225 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $49K3,413 at $14.25 | filing |
| 5 Dec 2025filed 5 Dec 2025 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $11K798 at $14.23 | filing |
| 25 Nov 2025filed 26 Nov 2025 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 8 Aug 2025filed 8 Aug 2025 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $15K2,217 at $6.99 | filing |
| 12 Feb 2025filed 14 Feb 2025 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —9,750 at $0.00 | filing |
| 12 Feb 2025filed 14 Feb 2025 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $16K2,861 at $5.59 | filing |
| 6 Dec 2024filed 10 Dec 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $6,980866 at $8.06 | filing |
| 27 Nov 2024filed 27 Nov 2024 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,000 at $0.00 | filing |
| 8 Aug 2024filed 9 Aug 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $19K1,466 at $12.73 | filing |
| 15 Jul 2024filed 15 Jul 2024 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,375 at $0.00 | filing |
| 15 Jul 2024filed 15 Jul 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $48K5,375 at $8.99 | filing |
| 15 Jul 2024filed 15 Jul 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $92K5,375 at $17.08 | filing |
| 12 Jul 2024filed 15 Jul 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $34K2,271 at $15.04 | filing |
News
Comparing Amphastar Pharmaceuticals (NASDAQ:AMPH) & Enanta Pharmaceuticals (NASDAQ:ENTA)ENTA · tickerreport.com · 13 Oct 2026Contrasting Enanta Pharmaceuticals (NASDAQ:ENTA) and Scilex (NASDAQ:SCLX)ENTA · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Scott T. Rottinghaus; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.